ABCB1 (MDR1) rs1045642 is associated with increased overall survival in plasma cell myeloma

References

• Sanford S, Deborshi R, Schindler M. Cell biological mechanisms of multidrug resistance in tumors. Proc Natl Acad Sci USA 1994; 91: 3497–3504
   PubMed Web of Science ®Google Scholar
• Sanford S, Deborshi R, Schindler M. Intracellular pH and the control of multidrug resistance. Proc Natl Acad Sci USA 1994; 91: 1128–1132
   PubMed Web of Science ®Google Scholar
• Juranka P F, Zastawny R L, Ling V. P-glycoprotein: multidrug-resistance and a superfamily of membrane-associated transport proteins. FASEB J 1989; 3: 2583–2592
   PubMed Web of Science ®Google Scholar
• Consoli U, Santonocito A, Stagno F, Fiumara P, Privitera A, Parisi G, et al. Multidrug resistance mechanisms in chronic lymphocytic leukaemia. Br J Haematol 2002; 116: 774–780
   PubMed Web of Science ®Google Scholar
• Matthews C, Catherwood M A, Larkin A M, Clynes M, Morris T C, Alexander H D. MDR-1, but not MDR-3 gene expression, is associated with unmutated IgVH genes and poor prognosis chromosomal aberrations in chronic lymphocytic leukemia. Leuk Lymphoma 2006; 47: 2308–2313
   PubMed Web of Science ®Google Scholar
• de Figueiredo-Pontes L L, Pintao M C, Oliveira L C, Dalmazzo L F, Jacomo R H, Garcia A B, et al. Determination of P-glycoprotein, MDR-related protein 1, breast cancer resistance protein, and lung-resistance protein expression in leukemic stem cells of acute myeloid leukemia. Cytometry B Clin Cytom 2008; 74: 163–168
   PubMed Web of Science ®Google Scholar
• Ohsawa M, Ikura Y, Fukushima H, Shirai N, Sugama Y, Suekane T, et al. Immunohistochemical expression of multidrug resistance proteins as a predictor of poor response to chemotherapy and prognosis in patients with nodal diffuse large B-cell lymphoma. Oncology 2005; 68: 422–431
   PubMed Web of Science ®Google Scholar
• Grogan T M, Spier C M, Salmon S E, Matzner M, Rybski J, Weinstein R S, et al. P-glycoprotein expression in human plasma cell myeloma: Correlation with prior chemotherapy. Blood 1993; 81: 490–495
   PubMed Web of Science ®Google Scholar
• Morita N, Yasumori T, Nakayama K. Human MDR1 polymorphism: G2677T/A and C3435T have no effect on MDR1 transport activities. Biochem Pharmacol 2003; 65: 1843–1852
   PubMed Web of Science ®Google Scholar
• Kimchi-Sarfaty C, Oh J M, Kim I W, Sauna Z E, Calcagno A M, Ambudkar S V, et al. A ‘silent’ polymorphism in the MDR1 gene changes substrate specificity. Science 2007; 315: 525–528
   PubMed Web of Science ®Google Scholar
• Salama N N, Yang Z, Bui T, Ho R J. MDR1 haplotypes significantly minimize intracellular uptake and transcellular P-gp substrate transport in recombinant LLC-PK1 cells. J Pharm Sci 2006; 95: 2293–2308
   PubMed Web of Science ®Google Scholar
• Hoffmeyer S, Burk O, von Richter O, Arnold H P, Brockmoller J, Johne A, et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 2000; 97: 3473–3478
   PubMed Web of Science ®Google Scholar
• Hitzl M, Drescher S, van der Kuip H, Schaffeler E, Fischer J, Schwab M, et al. The C3435T mutation in the human MDR1 gene is associated with altered efflux of the P-glycoprotein substrate rhodamine 123 from CD56+ natural killer cells. Pharmacogenetics 2001; 11: 293–298
   PubMedGoogle Scholar
• Song P, Lamba J K, Zhang L, Schuetz E, Shukla N, Meibohm B, et al. G2677T and C3435T genotype and haplotype are associated with hepatic ABCB1 (MDR1) expression. J Clin Pharmacol 2006; 46: 373–379
   PubMed Web of Science ®Google Scholar
• Buda G, Maggini V, Galimberti S, Martino A, Giuliani N, Morabito F, et al. MDR1 polymorphism influences the outcome of multiple myeloma patients. Br J Haematol 2007; 137: 454–456
   PubMed Web of Science ®Google Scholar
• Schilthuizen C, Broyl A, van der Holt B, de Knegt Y, Lokhorst H, Sonneveld P. Influence of genetic polymorphisms in CYP3A4, CYP3A5, GSTP1, GSTM1, GSTT1 and MDR1 genes on survival and therapy-related toxicity in multiple myeloma. Haematologica 2007; 92: 277–278
   PubMed Web of Science ®Google Scholar
• Maggini V, Buda G, Martino A, Presciuttini S, Galimberti S, Orciuolo E, et al. MDR1 diplotypes as prognostic markers in multiple myeloma. Pharmacogenet Genomics 2008; 18: 383–389
   PubMed Web of Science ®Google Scholar
• Cascorbi I, Gerloff T, Johne A, Meisel C, Hoffmeyer S, Schwab M, et al. Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin Pharmacol Ther 2001; 69: 169–174
   PubMed Web of Science ®Google Scholar
• Chowbay B, Li H, David M, Cheung Y B, Lee E J. Meta-analysis of the influence of MDR1 C3435T polymorphism on digoxin pharmacokinetics and MDR1 gene expression. Br J Clin Pharmacol 2005; 60: 159–171
   PubMed Web of Science ®Google Scholar
• Calado R T, Falcao R P, Garcia A B, Gabellini S M, Zago M A, Franco R F. Influence of functional MDR1 gene polymorphisms on P-glycoprotein activity in CD34+ hematopoietic stem cells. Haematologica 2002; 87: 564–568
   PubMed Web of Science ®Google Scholar
• Nauck M, Stein U, von Karger S, Marz W, Wieland H. Rapid detection of the C3435T polymorphism of multidrug resistance gene 1 using fluorogenic hybridization probes. Clin Chem 2000; 46: 1995–1997
   PubMed Web of Science ®Google Scholar
• Packer B R, Yeager M, Burdett L, Welch R, Beerman M, Qi L, et al. SNP500Cancer: a public resource for sequence validation, assay development, and frequency analysis for genetic variation in candidate genes. Nucleic Acids Res 2006; 1(34)D617–D621
   Google Scholar
• Jamroziak K, Mlynarski W, Balcerczak E, Mistygacz M, Trelinska J, Mirowski M, et al. Functional C3435T polymorphism of MDR1 gene: an impact on genetic susceptibility and clinical outcome of childhood acute lymphoblastic leukemia. Eur J Haematol 2004; 72: 314–321
   PubMed Web of Science ®Google Scholar